NCT06636682: An ongoing trial by Cellvax Therapeutics Inc
This trial is ongoing. It must report results 2 years, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06636682 |
|---|---|
| Title | A Multicenter, Adaptive, Phase 2, Randomized, Open-label Study of Irradiated Autologous Cellular Vaccine in Men With High-Risk Prostate Cancer Following Prostatectomy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 14, 2024 |
| Completion date | Feb. 2, 2027 |
| Required reporting date | Feb. 2, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |